Unknown

Dataset Information

0

Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axis.


ABSTRACT: Cancer cells exploit CD47 overexpression to inhibit phagocytic elimination and neoantigen processing via the myeloid CD47-SIRPα axis and thereby indirectly evade adaptive T cell immunity. Here, we report on a hitherto unrecognized direct immunoinhibitory feature of cancer cell-expressed CD47. We uncovered that in response to IFNγ released during cognate T cell immune attack, cancer cells dynamically enhance CD47 cell surface expression, which coincides with acquiring adaptive immune resistance toward pro-apoptotic effector T cell mechanisms. Indeed, CRISPR/Cas9-mediated CD47-knockout rendered cancer cells more sensitive to cognate T cell immune attack. Subsequently, we developed a cancer-directed strategy to selectively overcome CD47-mediated adaptive immune resistance using bispecific antibody (bsAb) CD47xEGFR-IgG2s that was engineered to induce rapid and prolonged cancer cell surface displacement of CD47 by internalization. Treatment of CD47pos cancer cells with bsAb CD47xEGFR-IgG2s potently enhanced susceptibility to cognate CD8pos T cells. Targeting CD47-mediated adaptive immune resistance may open up new avenues in cancer immunotherapy.

SUBMITTER: Hendriks MAJM 

PROVIDER: S-EPMC8632294 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9280883 | biostudies-literature
| S-EPMC8157794 | biostudies-literature
| S-EPMC10768116 | biostudies-literature
| S-EPMC7802363 | biostudies-literature
| S-EPMC9969460 | biostudies-literature
| S-EPMC6338872 | biostudies-literature
| S-EPMC9927946 | biostudies-literature
| S-EPMC6796872 | biostudies-literature
| S-EPMC8699673 | biostudies-literature
| S-EPMC9732525 | biostudies-literature